Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. | Biomedicines | 2022 | 35203446 | PubTator, text mining | PubMed |
| Novel Interactive Tool for Breast and Ovarian Cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study. | J Med Internet Res | 2022 | 35200148 | PubTator, text mining | PubMed |
| Type-I Interferon Signaling in Fanconi Anemia. | Front Cell Infect Microbiol | 2022 | 35198459 | PubTator, text mining | PubMed |
| Estimating the proportion of pathogenic variants from breast cancer case-control data: Application to calibration of ACMG/AMP variant classification criteria. | Hum Mutat | 2022 | 35191126 | PubTator, text mining | PubMed |
| Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria. | Sci Rep | 2022 | 35190596 | PubTator, text mining | PubMed |
| Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics. | Front Oncol | 2022 | 35186721 | PubTator, text mining | PubMed |
| Lift the Veil of Breast Cancers Using 4 or Fewer Critical Genes. | Cancer Inform | 2022 | 35185329 | PubTator, text mining | PubMed |
| LncRNA SND1-IT1 facilitates TGF-β1-induced epithelial-to-mesenchymal transition via miR-124/COL4A1 axis in gastric cancer. | Cell Death Discov | 2022 | 35184134 | PubTator, text mining | PubMed |
| Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. | JAMA Netw Open | 2022 | 35171259 | PubTator, text mining | PubMed |
| Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience. | Gynecol Oncol Rep | 2022 | 35169607 | PubTator, text mining | PubMed |
| Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. | Geburtshilfe Frauenheilkd | 2022 | 35169388 | PubTator, text mining | PubMed |
| Cytoprotective Activity of Polyamines Is Associated with the Alternative Splicing of RAD51A Pre-mRNA in Normal Human CD4+ T Lymphocytes. | Int J Mol Sci | 2022 | 35163785 | PubTator, text mining | PubMed |
| Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins. | Int J Mol Sci | 2022 | 35163748 | PubTator, text mining | PubMed |
| Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. | Int J Mol Sci | 2022 | 35163129 | PubTator, text mining | PubMed |
| Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2. | Cells | 2022 | 35159349 | PubTator, text mining | PubMed |
| Homologous Recombination-Enhancing Factors Identified by Comparative Transcriptomic Analyses of Pluripotent Stem Cell of Human and Common Marmoset. | Cells | 2022 | 35159172 | PubTator, text mining | PubMed |
| Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? | Cancers (Basel) | 2022 | 35159068 | PubTator, text mining | PubMed |
| PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. | Cancers (Basel) | 2022 | 35158866 | PubTator, text mining | PubMed |
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. | Lancet Oncol | 2022 | 35157830 | PubTator, text mining | PubMed |
| Metnase and EEPD1: DNA Repair Functions and Potential Targets in Cancer Therapy. | Front Oncol | 2022 | 35155245 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=60